Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 6
2004 5
2005 8
2006 6
2007 4
2008 7
2009 7
2010 11
2011 12
2012 13
2013 10
2014 14
2015 6
2016 7
2017 6
2018 3
2019 6
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

121 results
Results by year
Filters applied: . Clear all
Page 1
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.
Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. Kay J, et al. Ann Rheum Dis. 2018 Feb;77(2):165-174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2. Ann Rheum Dis. 2018. PMID: 28866648
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies.
Doevendans E, Schellekens H. Doevendans E, et al. Among authors: schellekens h. Antibodies (Basel). 2019 Mar 5;8(1):21. doi: 10.3390/antib8010021. Antibodies (Basel). 2019. PMID: 31544827 Free PMC article. Review.
Are we ready to close the discussion on the interchangeability of biosimilars?
Ebbers HC, Schellekens H. Ebbers HC, et al. Among authors: schellekens h. Drug Discov Today. 2019 Oct;24(10):1963-1967. doi: 10.1016/j.drudis.2019.06.016. Epub 2019 Jun 26. Drug Discov Today. 2019. PMID: 31254488 Free article. Review.
Protein Quality Testing in the Era of Personalized Medicine.
Doevendans E, Schellekens H. Doevendans E, et al. Among authors: schellekens h. J Pharm Sci. 2020 Oct;109(10):2962-2968. doi: 10.1016/j.xphs.2020.07.009. Epub 2020 Jul 14. J Pharm Sci. 2020. PMID: 32673626
Safety and efficacy of biosimilars in oncology.
Schellekens H, Smolen JS, Dicato M, Rifkin RM. Schellekens H, et al. Lancet Oncol. 2016 Nov;17(11):e502-e509. doi: 10.1016/S1470-2045(16)30374-6. Lancet Oncol. 2016. PMID: 27819248 Review.
Immunogenicity of biopharmaceuticals.
Kessler M, Goldsmith D, Schellekens H. Kessler M, et al. Among authors: schellekens h. Nephrol Dial Transplant. 2006 Oct;21 Suppl 5:v9-12. doi: 10.1093/ndt/gfl476. Nephrol Dial Transplant. 2006. PMID: 16959792 Review.
Making individualized drugs a reality.
Schellekens H, Aldosari M, Talsma H, Mastrobattista E. Schellekens H, et al. Nat Biotechnol. 2017 Jun;35(6):507-513. doi: 10.1038/nbt.3888. Epub 2017 Jun 5. Nat Biotechnol. 2017. PMID: 28581491 No abstract available.
The immunogenicity of biopharmaceuticals.
Schellekens H. Schellekens H. Neurology. 2003 Nov 11;61(9 Suppl 5):S11-2. doi: 10.1212/01.wnl.0000092358.51502.c0. Neurology. 2003. PMID: 14610103 Review. No abstract available.
Liposome-targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation.
Aldosari MH, de Vries RP, Rodriguez LR, Hesen NA, Beztsinna N, van Kuilenburg ABP, Hollak CEM, Schellekens H, Mastrobattista E. Aldosari MH, et al. Among authors: schellekens h. Eur J Pharm Biopharm. 2019 Apr;137:185-195. doi: 10.1016/j.ejpb.2019.02.019. Epub 2019 Feb 25. Eur J Pharm Biopharm. 2019. PMID: 30818011
Feasibility Study for Bedside Production of Recombinant Human Acid α-Glucosidase: Technical and Financial Considerations.
Aldosari MH, den Hartog M, Ganizada H, Evers MJW, Mastrobattista E, Schellekens H. Aldosari MH, et al. Among authors: schellekens h. Curr Pharm Biotechnol. 2020;21(6):467-479. doi: 10.2174/1389201021666200217113049. Curr Pharm Biotechnol. 2020. PMID: 32065100
121 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback